BOCA RATON, Fla., Feb. 21 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) will announce 2006 fourth quarter and
year- end financial results on Monday, March 12, 2007, after market close.
The company will also host a live webcast at 4:30 p.m. ET. Please note that
only the previously announced date for the year-end financial results has
changed and that all call-in information will remain the same.
The live webcast can be accessed at http://phx.corporate-
ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=1473397 or via
the Nabi Biopharmaceuticals website at http://www.nabi.com. If you do not
have Internet access, the U.S./Canada call-in number is 866-713-8310
conference code 57672232, and the international call-in number is
617-597-5308 conference code 57672232. An audio replay will be available
for U.S./Canada callers at 888-286-8010 conference code 51818152, and for
international callers at 617- 801-6888 conference code 51818152.
An archived version of the webcast will be available at the same
Internet address through March 19, 2007. The audio replay will also be
available through March 19, 2007. The press release will be available on
the company's website at http://www.nabi.com.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. The company has two products on the market
today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM)
(allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on
developing products that address unmet medical needs and offer commercial
opportunities in our core business areas: Hepatitis and transplant,
Gram-positive bacterial infections and nicotine addiction. For a complete
list of pipeline products, please go to:
http://www.nabi.com/pipeline/index.php. The company is headquartered in
Boca Raton, Florida. For additional information about Nabi
Biopharmaceuticals, please visit our website: http://www.nabi.com.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
http://www.nabi.com/pipeline/index.php
CONTACT:
Thomas E. Rathjen, Vice President, Investor
Relations, of Nabi Biopharmaceuticals, +1-561-989-5800
|
